HK1243943A1 - 使用抗IL-1α抗體治療癌症 - Google Patents
使用抗IL-1α抗體治療癌症Info
- Publication number
- HK1243943A1 HK1243943A1 HK18103522.1A HK18103522A HK1243943A1 HK 1243943 A1 HK1243943 A1 HK 1243943A1 HK 18103522 A HK18103522 A HK 18103522A HK 1243943 A1 HK1243943 A1 HK 1243943A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cancer
- treatment
- antibodies
- immunization
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80216606P | 2006-05-22 | 2006-05-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1243943A1 true HK1243943A1 (zh) | 2018-07-27 |
Family
ID=38670649
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18103522.1A HK1243943A1 (zh) | 2006-05-22 | 2018-03-13 | 使用抗IL-1α抗體治療癌症 |
Country Status (15)
Country | Link |
---|---|
US (3) | US20100040574A1 (zh) |
EP (1) | EP2109623B1 (zh) |
JP (3) | JP2009537628A (zh) |
CN (3) | CN101472948A (zh) |
AT (1) | ATE528319T1 (zh) |
AU (1) | AU2007252990B2 (zh) |
CA (1) | CA2652870C (zh) |
CY (1) | CY1112288T1 (zh) |
DK (1) | DK2109623T3 (zh) |
ES (1) | ES2374845T3 (zh) |
HK (1) | HK1243943A1 (zh) |
PL (1) | PL2109623T3 (zh) |
PT (1) | PT2109623E (zh) |
SI (1) | SI2109623T1 (zh) |
WO (1) | WO2007135546A2 (zh) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006274698B2 (en) * | 2005-08-02 | 2011-06-09 | Xbiotech, Inc. | Diagnosis, treatment, and prevention of vascular disorders using IL-1a autoantibodies |
US20110008282A1 (en) * | 2006-05-15 | 2011-01-13 | Xbiotech, Inc. | IL-1alpha immunization induces autoantibodies protective against atherosclerosis |
PL3085773T3 (pl) * | 2008-05-30 | 2021-01-11 | Xbiotech, Inc | Zastosowanie przeciwciał il-1 alfa |
JP5976319B2 (ja) * | 2008-09-12 | 2016-08-23 | エックスバイオテク,インコーポレイテッドXbiotech,Inc. | 病原性単球の標的化 |
TWI615405B (zh) | 2010-05-14 | 2018-02-21 | 艾伯維有限公司 | Il-1結合蛋白 |
KR102167261B1 (ko) | 2010-06-18 | 2020-10-20 | 엑스바이오테크, 인크. | 관절염 치료 |
AU2015271978B2 (en) * | 2010-08-23 | 2017-10-26 | Xbiotech Inc. | Treatment for neoplastic diseases |
AU2011293554B9 (en) * | 2010-08-23 | 2015-03-19 | Xbiotech Inc. | Treatment for neoplastic diseases |
AU2015201228B2 (en) * | 2010-08-23 | 2016-02-11 | Xbiotech Inc. | Treatment for neoplastic diseases |
US9724409B2 (en) | 2011-04-01 | 2017-08-08 | Xbiotech, Inc. | Treatment of inflammatory skin disease |
MX356808B (es) * | 2011-09-23 | 2018-06-14 | Xbiotech Inc | Uso de una composición farmacéutica que comprende un anticuerpo anti-il-1a para el tratamiento de la caquexia. |
US9545441B2 (en) | 2012-09-18 | 2017-01-17 | Xbiotech, Inc. | Treatment of diabetes |
WO2018150265A1 (en) | 2017-02-16 | 2018-08-23 | Xbiotech, Inc. | Treatment of hidradenitis suppurativa |
US10975146B2 (en) | 2018-06-29 | 2021-04-13 | Cedars-Sinai Medical Center | Interleukin-1 inhibition for combination treatment of pancreatic cancer |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH652145A5 (de) * | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
US5672347A (en) * | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
US5168062A (en) * | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4965198A (en) * | 1985-12-24 | 1990-10-23 | Konica Corporation | Monoclonal antibody and method of manufacturing hybridoma producing the same |
DE3631229A1 (de) * | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
JPH06339394A (ja) * | 1986-11-13 | 1994-12-13 | Otsuka Pharmaceut Co Ltd | ヒトインターロイキン−1αに対するモノクローナル抗体 |
US5034316A (en) * | 1987-03-30 | 1991-07-23 | The Regents Of The University Of California | In vitro human monoclonal IgG rheumatoid factor autoantibody |
JPH02157231A (ja) * | 1988-12-07 | 1990-06-18 | Bio Kagaku Kenkyusho:Kk | 細胞増殖抑制剤 |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB9122820D0 (en) * | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
AU5355094A (en) * | 1992-10-14 | 1994-05-09 | Sterling Winthrop Inc. | Therapeutic and diagnostic imaging compositions and methods |
DE69427928T3 (de) * | 1993-03-05 | 2012-05-10 | Bayer Healthcare Llc | Humane monoklonale anti-TNF alpha Antikörper |
US5959085A (en) * | 1993-11-23 | 1999-09-28 | Schering Corporation | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
US6140470A (en) * | 1995-06-30 | 2000-10-31 | Yale University | Human monoclonal anti-tumor antibodies |
US6090382A (en) * | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
SE9802402D0 (sv) * | 1998-07-03 | 1998-07-03 | Karolinska Innovations Ab | Method of diagnosing cardiovascular disease and early atherosclerosis |
US20030040617A9 (en) * | 1999-03-12 | 2003-02-27 | Rosen Craig A. | Nucleic acids, proteins and antibodies |
US20030232054A1 (en) * | 2000-01-25 | 2003-12-18 | Tang Y. Tom | Novel nucleic acids and polypeptides |
US20020131954A1 (en) * | 2000-05-02 | 2002-09-19 | Tobinick Edward L. | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
US20030026806A1 (en) * | 2000-10-27 | 2003-02-06 | Amgen Inc. | Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof |
CA2497884C (en) * | 2002-09-06 | 2013-10-22 | Brian Varnum | Therapeutic human anti-il-1r1 monoclonal antibody |
HN2004000285A (es) * | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
US7799327B2 (en) * | 2003-12-24 | 2010-09-21 | Henry John Smith | Autoantibodies utilized as carrier agents for pharmaceutical compounds used in cancer treatment |
US7105183B2 (en) * | 2004-02-03 | 2006-09-12 | The Regents Of The University Of California | Chlorite in the treatment of neurodegenerative disease |
WO2006001967A2 (en) * | 2004-05-25 | 2006-01-05 | Sloan-Kettering Institute For Cancer Research | Migrastatin analogs in the treatment of cancer |
AU2006274698B2 (en) * | 2005-08-02 | 2011-06-09 | Xbiotech, Inc. | Diagnosis, treatment, and prevention of vascular disorders using IL-1a autoantibodies |
US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US20110008282A1 (en) * | 2006-05-15 | 2011-01-13 | Xbiotech, Inc. | IL-1alpha immunization induces autoantibodies protective against atherosclerosis |
WO2007132338A2 (en) * | 2006-05-15 | 2007-11-22 | Xbiotech Inc. | IL-1α IMMUNIZATION INDUCES AUTOANTIBODIES PROTECTIVE AGAINST ATHEROSCLEROSIS |
EP2446904B1 (en) * | 2006-05-30 | 2015-04-29 | Genentech, Inc. | Anti-CD22 antibodies, their immunoconjugates and uses thereof |
PL3085773T3 (pl) * | 2008-05-30 | 2021-01-11 | Xbiotech, Inc | Zastosowanie przeciwciał il-1 alfa |
JP5976319B2 (ja) * | 2008-09-12 | 2016-08-23 | エックスバイオテク,インコーポレイテッドXbiotech,Inc. | 病原性単球の標的化 |
-
2007
- 2007-05-22 SI SI200730797T patent/SI2109623T1/sl unknown
- 2007-05-22 US US12/302,066 patent/US20100040574A1/en not_active Abandoned
- 2007-05-22 CA CA2652870A patent/CA2652870C/en active Active
- 2007-05-22 CN CNA2007800231112A patent/CN101472948A/zh active Pending
- 2007-05-22 AU AU2007252990A patent/AU2007252990B2/en active Active
- 2007-05-22 CN CN2012100439005A patent/CN102580086A/zh active Pending
- 2007-05-22 EP EP07734628A patent/EP2109623B1/en active Active
- 2007-05-22 WO PCT/IB2007/001320 patent/WO2007135546A2/en active Application Filing
- 2007-05-22 DK DK07734628.6T patent/DK2109623T3/da active
- 2007-05-22 CN CN201710383172.5A patent/CN107158376A/zh active Pending
- 2007-05-22 PL PL07734628T patent/PL2109623T3/pl unknown
- 2007-05-22 ES ES07734628T patent/ES2374845T3/es active Active
- 2007-05-22 JP JP2009511597A patent/JP2009537628A/ja not_active Withdrawn
- 2007-05-22 PT PT07734628T patent/PT2109623E/pt unknown
- 2007-05-22 AT AT07734628T patent/ATE528319T1/de active
-
2012
- 2012-01-05 CY CY20121100014T patent/CY1112288T1/el unknown
-
2013
- 2013-01-25 JP JP2013011701A patent/JP5992843B2/ja active Active
-
2015
- 2015-07-03 JP JP2015134049A patent/JP6359492B2/ja active Active
-
2016
- 2016-02-02 US US15/013,469 patent/US20160159899A1/en not_active Abandoned
-
2018
- 2018-03-13 HK HK18103522.1A patent/HK1243943A1/zh unknown
-
2019
- 2019-02-08 US US16/271,235 patent/US20190169287A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2007135546A3 (en) | 2008-02-07 |
AU2007252990A1 (en) | 2007-11-29 |
JP2009537628A (ja) | 2009-10-29 |
JP2015166401A (ja) | 2015-09-24 |
CN102580086A (zh) | 2012-07-18 |
AU2007252990B2 (en) | 2011-10-27 |
CA2652870A1 (en) | 2007-11-29 |
PT2109623E (pt) | 2012-01-12 |
PL2109623T3 (pl) | 2012-03-30 |
US20160159899A1 (en) | 2016-06-09 |
ATE528319T1 (de) | 2011-10-15 |
WO2007135546A2 (en) | 2007-11-29 |
CA2652870C (en) | 2014-12-02 |
CY1112288T1 (el) | 2015-12-09 |
DK2109623T3 (da) | 2012-01-30 |
JP2013126990A (ja) | 2013-06-27 |
EP2109623A2 (en) | 2009-10-21 |
JP5992843B2 (ja) | 2016-09-14 |
US20190169287A1 (en) | 2019-06-06 |
ES2374845T3 (es) | 2012-02-22 |
JP6359492B2 (ja) | 2018-07-18 |
EP2109623B1 (en) | 2011-10-12 |
CN107158376A (zh) | 2017-09-15 |
US20100040574A1 (en) | 2010-02-18 |
CN101472948A (zh) | 2009-07-01 |
SI2109623T1 (sl) | 2012-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1243943A1 (zh) | 使用抗IL-1α抗體治療癌症 | |
HRP20181565T1 (hr) | Monoklonska protutijela protiv klaudina-18 za liječenje karcinoma | |
UA94452C2 (ru) | Гуманизированные моноклональные антитела к фактору роста гепатоцитов | |
EP2103628A4 (en) | MONOCLONAL ANTIBODY ANTI-CLAUDIN 3, AND TREATMENT AND DIAGNOSIS OF CANCER USING SUCH ANTIBODY | |
MY150756A (en) | Tumor theraphy with an anti-vegf antibody | |
MX2010002406A (es) | Terapia de combinacion con anticuerpos anti-cd20 de tipo i y de tipo ii. | |
NZ601588A (en) | Methods for treating breast cancer | |
UA99601C2 (ru) | Применение антитела к cd151 для лечения первичных опухолей | |
NZ589795A (en) | Use of LM-1 antibody which binds to NONO/nmt55 protein to prevent metastasis | |
TW200740845A (en) | Use of anti-MAdCAM antibodies for the treatment of coeliac disease and tropical sprue |